Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Gains from Sales and Divestitures (2023 - 2024)

Onconetix (ONCO) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $4852.0 as the latest value for Q3 2024.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $4852.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $4852.0, a N/A change, with the full-year FY2023 number at $6250.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $4852.0 for Q3 2024 at Onconetix, down from $140955.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $140955.0 in Q2 2024 to a low of $4852.0 in Q3 2024.